Achromatopsia Clinical Trial
Official title:
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3 and AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 or CNGA3
This study is a longer-term follow-up study for patients who participated in one of the clinical trials: AAV - CNGB3 retinal gene therapy for patients with achromatopsia, or AAV - CNGA3 retinal gene therapy for patients with achromatopsia.
The follow up study is designed to collect data on longer-term safety and efficacy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04124185 -
Natural History Study for Achromatopsia
|
||
Active, not recruiting |
NCT02610582 -
Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04041232 -
PBA Use for Treatment of ATF6-/- Patients
|
Early Phase 1 | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Completed |
NCT01846052 -
Clinical and Genetic Characterization of Individuals With Achromatopsia
|
N/A | |
Active, not recruiting |
NCT01648452 -
CNTF Implants for CNGB3 Achromatopsia
|
Phase 1/Phase 2 | |
Completed |
NCT03001310 -
Gene Therapy for Achromatopsia (CNGB3)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02935517 -
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
|
Phase 1/Phase 2 | |
Completed |
NCT03758404 -
Gene Therapy for Achromatopsia (CNGA3)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02599922 -
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
|
Phase 1/Phase 2 |